Page 12 - Read Online

Page 190 Paraskevas. Neuroimmunol Neuroinflammation 2020;7:183-93 I http://dx.doi.org/10.20517/2347-8659.2019.008

Alzheimer’s disease patients presenting as corticobasal syndrome. J Neurol Sci 2019;398:142-7.
15. Paraskevas GP, Constantinides VC, Pyrgelis ES, Kapaki E. Mixed small vessel disease in a patient with dementia with Lewy bodies.
Brain Sci 2019;9:E159.
16. Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, et al. Alzheimer’s disease-subcortical vascular disease spectrum in a
hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab 2016;36:95-113.
17. Peavy GM, Edland SD, Toole BM, Hansen LA, Galasko DR, et al. Phenotypic differences based on staging of Alzheimer’s
neuropathology in autopsy-confirmed dementia with Lewy bodies. Parkinsonism Relat Disord 2016;31:72-8.
18. van der Zande JJ, Steenwijk MD, Ten Kate M, Wattjes MP, Scheltens P, et al. Gray matter atrophy in dementia with Lewy bodies with and
without concomitant Alzheimer’s disease pathology. Neurobiol Aging 2018;71:171-8.
19. Savica R, Beach TG, Hentz JG, Sabbagh MN, Serrano GE, et al. Lewy body pathology in Alzheimer’s disease: A clinicopathological
prospective study. Acta Neurol Scand 2019;139:76-81.
20. Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, et al. Concomitant AD pathology affects clinical manifestation and
survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2017;88:113-8.
21. Bennett D, Schneider J, Bienias J, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer pathology and cerebral
infarctions. Neurology 2005;64:834-41.
22. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, et al. Clinical-neuropathological correlations in Alzheimer’s disease and
related dementias. Arch Neurol 1994;51:888-95.
23. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a
nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord 2013;35:239-48.
24. Jellinger KA, Bancher C. Neuropathology of Alzheimer’s disease: a critical update. J Neural Transm Suppl 1998;54:77-95.
25. Bancher C, Paulus W, Paukner K, Jellinger K. Neuropathologic diagnosis of Alzheimer disease: consensus between practicing
neuropathologists? Alzheimer Dis Assoc Disord 1997;11:207-19.
26. Forloni G. beta-Amyloid neurotoxicity. Funct Neurol 1993;8:211-25.
27. Iqbal K, Alonso A, Gong C, Khatoon S, Kudo T, et al. Molecular pathology of Alzheimer neurofibrillary degeneration. Acta Neurobiol
Exp (Wars) 1993;53:325-35.
28. Choi BH. Oxidative stress and Alzheimer’s disease. Neurobiol Aging 1995;16:675-8.
29. Smith-Swintosky VL, Mattson MP. Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration. J
Neural Transm Suppl 1994;44:29-45.
30. Stege GJ, Bosman GJ. The biochemistry of Alzheimer’s disease. Drugs Aging 1999;14:437-46.
31. Gonzalez B, Abud EM, Abud AM, Poon WW, Gylys KH. Tau spread, apolipoprotein e, inflammation, and more: rapidly evolving basic
science in Alzheimer disease. Neurol Clin 2017;35:175-90.
32. Rietdijk CD, van Wezel RJA, Garssen J, Kraneveld AD. Neuronal toll-like receptors and neuro-immunity in Parkinson’s disease,
Alzheimer’s disease and stroke. Neuroimmunol Neuroinflammation 2016;3:27-37.
33. Burns LH, Wang HY. Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s
disease. Neuroimmunol Neuroinflammation 2017;4:263-71.
34. Rentzos M, Zoga M, Paraskevas GP, Kapaki E, Rombos A, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer’s
disease and frontotemporal dementia. J Geriatr Psychiatry Neurol 2006;19:114-7.
35. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, et al. Detection of tau proteins in normal and Alzheimer’s disease
cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-34.
36. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, et al. Quantification of tau phosphorylated at
threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett
2000;285:49-52.
37. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, et al. Standardization of measurement of beta-amyloid(1-42) in
cerebrospinal fluid and plasma. Amyloid 2000;7:245-58.
38. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal
degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-45.
39. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, et al. Analytical performance and clinical utility of the INNOTEST
PHOSPHO-TAU181P assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin Chem Lab Med
2006;44:1472-80.
40. Sjögren M, Minthon L, Davidsson P, Granérus AK, Clarberg A, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in
frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) 2000;107:563-79.
41. Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, et al. The diagnostic value of cerebrospinal fluid tau protein in dementing and
nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol 2005;18:163-73.
42. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, et al. Improved discrimination of AD patients using beta-
amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-62.
43. Kapaki E, Paraskevas GP, Zalonis I, Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer’s disease diagnosis: discrimination
from normal ageing and other dementias in the Greek population. Eur J Neurol 2003;10:119-28.
44. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, et al. CSF biomarker profile and diagnostic value in vascular
dementia. Eur J Neurol 2009;16:205-11.
45. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron 2013;80:1347-58.